Brent Saunders

@bryan_johnson Try Re-Q. From @rapalogix

Results from my Feb 23 skin therapy: Improvements since treatment: > Brown spots: +71 percentile points (20th → 91st) ✅ > Pores: +25 percentile points ✅ > Spots: +25 percentile points✅ My skin age is 9 years younger than my chronological age (39 vs 48) and hasn't aged in five years since starting this project. Effectively a 9 year age reversal. Measured using VISIA multispectral clinical imaging, the most validated non-invasive skin analysis system available. Feb 23 treatment summary Technologies > Everesse RF > CoolPeel CO2 laser > BBL Each targeting a different skin depth so repair windows overlap without competing. Treatment details Everesse RF (200 pulses, Level 2.5 per cheek), CoolPeel CO2 laser (3.0W, 700 micron spacing), and BBL broadband light. Each targeting a different skin depth. Everesse drives heat into the dermis at 60-70°C, triggering fibroblast activation and collagen production that peaks 6-8 weeks later (about now), tightening the structural scaffolding that makes pores visible. CoolPeel ablates the surface layer of skin, physically removing melanin-loaded cells and forcing fresh keratinocytes to the surface. BBL destroys residual pigment one layer deeper through selective photothermolysis, where melanin absorbs light energy and self-destructs. Porphyrins dropped 13 points, which is expected. The treatments temporarily disrupt the follicular environment that bacteria need to thrive, and that recovers within 8-12 weeks. Goal was to do a triple-modality stack so the repair windows overlap without competing (dermis, epidermis, and chromophores).

Everyone is reacting to Jack Dorsey’s point about AI flattening organizations. He’s right that AI will reduce layers. We’re already seeing that. Small teams can do more, faster, with better output. But I think the conversation is a bit off. The issue was never “too many layers.” It’s too much complexity and not enough accountability. Great managers (A players) aren’t overhead. They’re force multipliers. They set the standard, develop talent, and make sure things actually get done. AI can accelerate the work, but it doesn’t replace ownership. The real shift is this: Fewer people. Higher bar. Less coordination. More execution. AI everywhere. Accountability doesn’t change. That’s where the advantage will come from.

Today, we're announcing Heaviside, our foundation model for electromagnetism. Trained on tens of millions of designs and over 20 years of proprietary simulation data, Heaviside predicts electromagnetic behavior from geometry in 13ms, which is 800,000x faster than a commercial solver. Heaviside is not a language model, and it’s not a surrogate model. Heaviside marks a new class of foundation model for physics which understands the fundamental relationships between materials, the geometries and the electromagnetic fields they generate. We’re releasing a research preview of Heaviside in Atlas RF Studio, an interactive agentic sandbox where you describe the EM behavior you want and the model generates the physical structure that produces it. @arenaphysica , we believe the implications of this class of model extend well beyond RF, as the frontier of exquisite hardware is electromagnetically-governed: wireless communication, radar, power delivery, high-speed computing, and the interconnects inside every chip on earth. In the months ahead, we’re excited to scale up Heaviside to broader frequency ranges, design spaces, and to support silicon-level designs, and deploy it with our closest partners and collaborators in service of their biggest design challenges. If you’ve read our thesis, this is just Step 2 in our pursuit of electromagnetic superintelligence. Read the full announcement and try Atlas RF Studio…tell us what you think: arenaphysica.com/publications/r…

New 24-month data from the pivotal U.S. clinical trial of the ELIOS™ System show positive results – meeting both primary effectiveness endpoints and delivering statistically significant reductions in intraocular pressure. Learn more: zurl.co/DsB6Y

Really special day in China with the @BauschLomb team. Spent time in business reviews, a global town hall, and meeting with customers. Nothing beats being there in person, listening, learning, and seeing the passion of our team and partners up close. It’s what makes this all real.

Take a direct approach to treating dry eye disease (DED) with MIEBO, an Rx drop with demonstrated efficacy and excellent tolerability across 2 pivotal trials and preclinical data supporting evaporation inhibition.¹⁻⁴

Our comprehensive product portfolio is designed to support consumers and eye care professionals worldwide in addressing eye health needs. Explore our full range of products below. U.S. Portfolio: zurl.co/6CB4i. Global Portfolio: zurl.co/I1nek.

@AlpBugraBasat Exactly!

@brentlsaunders Read this: retractionwatch.com/2015/06/10/exo…

I’m increasingly concerned about the proliferation of skincare products claiming “exosomes” and meaningful efficacy. A few basic diligence questions matter: • What exactly are the exosomes? Source, purification, and proper characterization • Are they actually stable in the formulation over time? • Is there real human clinical data showing benefit? The science may be promising, but many products (not all) make claims that seem far ahead of the evidence.

@howard @harrymoseleyd @roam 💪💪💪

Feb @roam !nvestor Update +14% ARR month over month +149% ARR year over year +116% NDR -Plans to accelerate growth to hit $10m in a year, T2D3 -Launches 9th Virtual Office Platform product, On-Air Events AI Productivity. Elite Culture. 93% Savings.

@howard Happy birthday my friend!

46

i’d consider starting this

A new global review published in Ophthalmology and Therapy discusses ocular redness trends, and how LUMIFY® redness reliever eye drops, when used as directed, are uniquely positioned to meet consumer needs. Learn more: zurl.co/5G0lV

Just read the @WSJ on the Supreme Court decision around Trump-era tariffs. So what happens next? Refunds for companies that already paid billions in duties? Does Congress step in? Or does the administration pivot to a new statutory mechanism to reimpose tariffs under different authority? My take: even if struck down, tariffs probably don’t disappear. They get redesigned. The policy goal stays. The legal pathway changes. Trade policy rarely moves backward. It just finds a new lane. Thoughts?

Thanks @YahooFinance and @BrianSozzi for spending time talking about @bauschlomb this morning!

@houmanhemmati @BauschLomb We are just getting started! Thank you.

@brentlsaunders @BauschLomb 👏 Congratulations Brent & @BauschLomb team! Blown away but not surprised. I have a feeling you’re just getting started. With all your innovation, there’ll be many greater wins in the future.

Our Earnings: 60 @BauschLomb

I’ll be live on Opening Bid today at 9:30 a.m. ET with @BrianSozzi to break down @BauschLomb earnings and what’s fueling our growth. lnkd.in/eMTu9XP6

Thank to the great team @BauschLomb We didn’t just grow in the fourth quarter – we grew smarter!

@howard So amazing! She is so talented! Go Lux!

My 10 year old wrote her own song and it’s coming out this week!